Hematologic disorders associated with cancer: II. White blood cell disorders

  • Jo-Anne M. Bessette
Part of the Cancer Treatment and Research book series (CTAR, volume 30)


White blood cell disorders that occur in patients with cancer include both quantitative and qualitative abnormalities. Many of the abnormalities of the white blood cell compartment are relatively benign and do not require treatment. These disturbances frequently are poorly understood in terms of etiology, sometimes waxing and waning with the disease process itself. The various interactions between the cancer and the white blood cell compartment remain to be elucidated.


Chronic Lymphocytic Leukemia Colony Stimulate Factor Large Cell Carcinoma Absolute Monocyte Count Bone Marrow Reserve 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Robinson WA. 1974. Granulocytosis in neoplasia. Ann NY Acad Sci 230:212–218.PubMedCrossRefGoogle Scholar
  2. 2.
    Sato N et al. 1979. Granulocytosis and colony-stimulating activity (CSA) produced by a human squamous cell carcinoma. Cancer 43:605–610.PubMedCrossRefGoogle Scholar
  3. 3.
    Suda T et al. 1980. A case of lung cancer associated with granulocytosis and production of colony-stimulating activity by the tumor. Br J Cancer 41:980–984.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Kimura N, Niho Y, Yanase T. 1982. A high level of colony-stimulating activity in a lung cancer patient with extensive leukocytosis, and the establishment of a CSA procucing cell line (KONT). Scand J Haematol 28:417–424.PubMedCrossRefGoogle Scholar
  5. 5..
    Bockman RS, Bellin A, Repo MA, Hickok NJ, Kameya T. 1983. In vivo and in vitro biological activities of two human cell lines derived from anaplastic lung cancers. Cancer Res 43:4571–4576.Google Scholar
  6. 6.
    Okabe T et al. 1984. Establishment of a human colony-stimulating factor-producing cell line from an undifferentiated large cell carcinoma of the lung. Cancer 54:1024–1029.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee MA, Lottsfeldt JL. 1984. Augmentation of neutrophilic granulocyte progenitors in the bone marrow of mice with tumor induced neutrophilia: Cytochemical study of in vitro colonies. Blood 64:499–506.PubMedGoogle Scholar
  8. 8.
    Takeda A et al. 1904. Clear cell carcinoma of the ovary with colony-stimulating-factor production. Cancer 54:1019–1023.CrossRefGoogle Scholar
  9. 9.
    Burgess AW, Metealf D. 1980. The nature and action of granulocyte-macrophage colony-stimulating factors. Blood 56:947–958.PubMedGoogle Scholar
  10. 10.
    Barrett O. 1970. Monocytosis in malignant disease. Ann Intern Med 73:991–992.PubMedCrossRefGoogle Scholar
  11. 11.
    Kaplan HS. 1980. Hodgkin’s disease, second edition. Harvard University press, Cambridge MA.Google Scholar
  12. 12.
    Zittoun R. 1976. Subacute and chronic myelomonocytic leukemia: a distinct haematologic entity. Br J Haematol 32:1–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Warnke RA, Kim H, Dorfman RF. 1975. Malignant histiocytosis (histiocytic medullary reticulosis); Clinicopathalogic study of 29 cases. Cancer 35:215–230.PubMedCrossRefGoogle Scholar
  14. 14.
    Gibson A. 1946. Monocytic leukemoid reaction associated with tuberculosis and a mediastinal teratoma. J Pathol Bacteriol 58:469–474.PubMedCrossRefGoogle Scholar
  15. 15.
    Rotman M, Ansley H, Togow L, Stowe S. 1977. Monocytosis a new observation during radiotherapy. Int. J Rad Oncol Biol Phys 2:117–121.CrossRefGoogle Scholar
  16. 16.
    Underwood JCE. 1974. Lymphoreticular infiltration in human tumors: prognositc and biological implications: a review. Br J Cancer 30:538–548.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lauder I, Aherne W, Stewart J, Sainsbury R. 1977. Macrophage infiltration of breast tumors: a prospective study. J Clin Pathol 30:563–568.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Luebbers EL et al. 1977. Heterogeneity and prognostic significance of breast tumors: A prospective study. J Clin Pathol 30:563–568.CrossRefGoogle Scholar
  19. 19.
    Lowe D, Jorizzo J, Hütt MSR. 1981. Tumor-associated eosinophilia; a review. J Clin Pathol. 34:1343–1348.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Kodama T et al. 1984. Large cell carcinoma of the lung associated with marked eosinophilia. Cancer 54:2313–2317.PubMedCrossRefGoogle Scholar
  21. 21.
    Reddy Sethu KS, Hyland RH, Alison RE, Sturgeon JFG, Hutcheon MA. 1984. Tumor-associated peripheral eosinophilia: two unusual cases. J. Clin Oncol 2:1165–1169.Google Scholar
  22. 22.
    Goetzl EJ et al. 1978. Production of a low molecular weight eosinophil polymorphonuclear leukocyte chemotactic factor by anaplastic squamous cell carcinoma of human lung. J Clin Invest 61:770–780.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Wasserman S et al. 1979. Tumor associated eosinophilotactic factor. N Engl J Med 290:420–424.CrossRefGoogle Scholar
  24. 24.
    Goetzl EJ et al. 1980. A novel eosinophil chemotactic factor derived from a histiocytic lymphoma of the central nervous system. Clin Exp Immunol 40:249–255.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Muggia EM, Ghossein NA, Wohl H. 1973. Eosinophilia following radiation therapy. Oncology 27:118–127.PubMedCrossRefGoogle Scholar
  26. 26.
    Rosenthal S, Schwartz JH, Canellos GP. 1977. Basophilia chronic granulocytic leukemia with hyperhistaminaemia. Br J Haematol 36:367–372.PubMedCrossRefGoogle Scholar
  27. 27.
    Pandolfi F et al. 1984. Classification of patients with T cell chronic lymphocytic leukemia and expansion of granulai lymphocytes: heterogeneity of Italian cases by a multiparameter analysis. J Clin Immunol 4:174–184.PubMedCrossRefGoogle Scholar
  28. 28.
    Lotzova E. 1984. The role of natural killer cells in immune surveillance against malignancies. Cancer Bull 36:215–225.Google Scholar
  29. 29.
    Semenzato G et al. 1984. Abnormal expansions of polyclonal large to small size granular lymphocytes: reactive or neoplastic process? Blood 63:1271–1278.PubMedGoogle Scholar
  30. 30.
    Taylor HG, Terebelo HR, Gameza. 1982. Lymphocytosis in a patient with malignant fibrous histiocytoma. Cancer 50:1563–1567.PubMedCrossRefGoogle Scholar
  31. 31.
    Gavarotti P, Boccadara M, Redoglia V, Golzio F, Pileri A. 1985. Reactive plasmacytosis. Case report and review of the literature. Acta Haematol 73:108–110.PubMedCrossRefGoogle Scholar
  32. 32.
    Kyle RA. 1978. Monoclonal gammopathies of undetermined significance: natural history of 241 cases. Am J Med 64:814–826.PubMedCrossRefGoogle Scholar
  33. 33.
    Isobe T, Osserman EF. 1975. Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann NY Acad Sci 190:507–512.CrossRefGoogle Scholar
  34. 34.
    Hoagland HC. 1982. Hematologic complications of cancer chemotherapy. Sem Oncol 9:95–101.Google Scholar
  35. 35.
    Olofsson T, Olsson I. 1980. Biochemical characterization of a leukemia-associated inhibitor (LAI) suppressing normal granulopoiesis in vitro. Blood 55:983–991.PubMedGoogle Scholar
  36. 36.
    Bognacki J, Broxmeyer HE, Lobue J: 1981. Isolation and biochemical characterization of leukemia-associated inhibitory activity that suppresses colony and cluster formation of cells. Biochem. Biophys. Acta 672:176–190.PubMedCrossRefGoogle Scholar
  37. 37.
    Olsson I, Olofsson T. 1985. Production characteristics and mode of action of hemopoietic growth inhibitors in myeloid leukemias (editorial). Med. Oncol Tumor Pharmacother 2:1–6.PubMedGoogle Scholar
  38. 38.
    Vaudaux P et al. 1984. Adriamycin impairs phagocytic function and induces morphologic alterations in human neutrophils. Cancer 54:400–410.PubMedCrossRefGoogle Scholar
  39. 39.
    Matamoros MC, Walker BK, Van Dyke K, Van Dyke CJ. 1983. Effect of cancer chemotherapeutic agents on the chemiluminescence of human granulocytes. Pharmacol 27:29–39.CrossRefGoogle Scholar
  40. 40.
    Samak R, Edelstein R, Bogucki D, Samak M, Israel L. 1980. Testing the monocyte-macrophage system in human cancer. Biomedicine 32:165–169.PubMedGoogle Scholar
  41. 41.
    Boetchu DA, Leonard EJ. 1974. Abnormal monocyte chemotactic response in cancer patients. J Natl Cancer Inst 52:1091–1099.Google Scholar
  42. 42.
    Snyderman R, Pike MC. 1976. An inhibitor of macrophage Chemotaxis produced by neoplasms. Science 192:370–372.PubMedCrossRefGoogle Scholar
  43. 43.
    DeYoung NJ, Gill PG. 1984. Monocyte antibody-dependent cellular cytotoxicity in cancer patients. Cancer Immunol. Immunother 18:54–58.CrossRefGoogle Scholar
  44. 44.
    Balm FAJM et al. 1984. Monocuclear phagocyte function in head and neck cancer. Cancer 54:1010–1015.PubMedCrossRefGoogle Scholar
  45. 45.
    Romagnani S, Ferrini PLR, Ricci M. 1985. The immune derangement in Hodgkin’s disease. Sem Hematol 22:41–55.Google Scholar
  46. 46.
    Watanobe T et al. 1985. T cell subsets in patients with gastric cancer. Oncology 42:89–91.CrossRefGoogle Scholar
  47. 47.
    Hayashi Y et al. 1984. Peripheral T gamma lymphocyte population in head and neck cancer. Cancer Immunol. Immunother 17:160–164.PubMedCrossRefGoogle Scholar
  48. 48.
    McCluskey DR, Roy AD, Abram WP, Martin WMC. 1983. T Lymphocyte subsets in the peripheral blood of patients with benign and malignant breast disease. Br J Cancer 47:307–309.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1986

Authors and Affiliations

  • Jo-Anne M. Bessette

There are no affiliations available

Personalised recommendations